Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;174(1):137-138.
doi: 10.7326/M20-1468. Epub 2020 Sep 8.

Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study

Christine M Durand  1 , Brittany Barnaba  1 , Sile Yu  1 , Diane M Brown  1 , Michael A Chattergoon  1 , Nichole Bair  1 , Fizza F Naqvi  1 , Mark Sulkowski  1 , Dorry L Segev  1 , Niraj M Desai  1
Affiliations

Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C-Viremic Donors to Hepatitis C-Negative Recipients: An Open-Label Nonrandomized Study

Christine M Durand et al. Ann Intern Med. 2021 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. HCV RNA in HCV-viremic donors and HCV-negative recipients who received prophylaxis.
HCV plasma RNA log10 in donors at organ recovery shown to the left of the dashed line and recipient HCV plasma RNA to the right on post-operative day (POD) 1 and 4, on prophylaxis weeks (PW) 1, 2, 4 and after prophylaxis on follow-up week (FW) 12. The lower limit of quantification (LLOQ) of the HCV RNA assay is 1.18 log10 IU/mL. HCV RNA values <LLOQ target not detected are shown on the zero line and values <LLOQ target detected not quantifiable are halfway between zero and 1.18 log10 IU/mL, the LLOQ. Donor and recipient pairs share the same symbol. Color corresponds to HCV genotype (GT). Five recipients (1,4,5,7,10) had no virus detected at all post-transplant timepoints. Two recipients (2,3) had HCV RNA <LLOQ, target detected on POD 1 and 4 and no HCV detected at all later timepoints. Three recipients (6,8,9) had low-level viremia (range 34–161 IU/mL) in the first week post-transplant. Overall, the proportion of recipients with HCV RNA <LLOQ at FW12 after prophylaxis was 100% (95% confidence interval 69–100%).
See this image and copyright information in PMC

References

    1. Goldberg D, Reese PP. Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis C virus-infected donors into hepatitis C virus-negative patients. Semin Dial. 2019;32(2):179–86. - PubMed
    1. Durand CM, Bowring MG, Brown DM, Chattergoon MA, Massaccesi G, Bair N, et al. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann Intern Med. 2018;168(8):533–40. - PMC - PubMed
    1. Sise ME, Strohbehn IA, Chute DF, Gustafson J, Van Deerlin VM, Smith JR, et al. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney Int Rep. 2020;5(4):459–67. - PMC - PubMed
    1. Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, et al. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N Engl J Med. 2019;380(17):1606–17. - PMC - PubMed
    1. Gupta G, Yakubu I, Bhati CS, Zhang Y, Kang L, Patterson JA, et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am J Transplant. 2020;20(3):739–51. - PubMed

Publication types